From The Stage

Noninvasive Liquid Biopsy Assays Integrating Tumor and Immune Biomarkers Prove to Be Promising Tools in Immuno-Oncology

Posted by BioAgilytix / / Immuno-oncology

Tumor tissue biopsies have been the traditional method of identifying and analyzing cancer cells. But in addition to being invasive and risky, they have many limitations. Tumor accessibility is often problematic as are issues with monitoring the progression of disease. Tissue samples from a single location don’t always provide a full picture of a tumor’s genetic heterogeneity, limiting accuracy. The more data oncologists have about a patient’s cancer, including genetic information, the more precisely it can be diagnosed, treated, and monitored. Immunotherapy has quickly evolved as a promising treatment modality…

Evaluation of CAR T-Cell Therapy Toxicities by Measurement of Cytokines During Therapy

Posted by / / Immuno-oncology

T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). CAR-T cells have demonstrated clinical efficacy in hematologic malignancies and targeting solid tumors. However, CAR-T therapy also can elicit cytokine release syndrome (CRS) cytotoxicity. This unwanted release of cytokines has also been seen following the infusion of therapeutic monoclonal antibodies (mAbs), systemic interleukin-2 (IL-2), and the bispecific CD19-CD3 T-cell engaging antibody blinatumomab.

Immuno-oncology in 2018: Overcoming Challenges to Revolutionize Cancer Treatment

Posted by / / BioAgilytix Insight, Immuno-oncology

Many immuno-oncology therapies are seeing success and showing promise for the future, including CAR-T cells, tumor-infiltrating lymphocytes (TILs), checkpoint inhibitors, and natural killer cell therapies. However, there are still many challenges (e.g. cytokine release syndrome in CAR-T therapies) that we as scientists must deal with when working in this new arena of drug development.

CAR T-Cell Therapy: Changing the Way Cancer is Treated

Posted by / / BioAgilytix Insight, Immuno-oncology

One of the most promising types of immunotherapy uses adoptive cell transfer (ACT). While all types of ACT are in their early days of development relatively speaking, one method showing great potential is chimeric antigen receptor T-cell therapy, or CAR-T.

Immuno-oncology: Advancing Therapeutic Options for Treating Human Cancers

Posted by / / BioAgilytix Insight, Immuno-oncology

The clinical landscape for cancer is currently undergoing an exciting shift. Treatment based around generic chemotherapies may be taking a back seat to a host of new, targeted therapies as scientists and doctors are beginning to leverage patients’ own immune systems to eliminate cancer cells – and finding success. While the treatment of cancer by immunological tools can be traced back to the early 1900s, recent advancements in assay methods and technologies are finally bringing new levels of immune-based curative cancer treatments, and possibly even the eradication of some cancer…